News Esperion and Daiichi Sankyo square up on Nexletol milestone Companies can't see eye to eye on the recently reported data from the CLEAR outcomes study.
News Nexletol shows CLEAR benefit in cardiovascular outcome trial Will a 13% improvement in MACE over placebo be enough to lift lacklustre sales growth?
News ESMO26: Takeda preps filings on CLDN18.2 gastric cancer data Takeda and Innovent's CLDN18.2-targeting ADC, arcotatug tavatecan, will be filed in Japan on the back of positive survival data in gastric cancer.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
